This trial is evaluating whether Consolidative Durvalumab will improve 1 primary outcome and 2 secondary outcomes in patients with Stage III Lung Cancer. Measurement will happen over the course of Twelve months from the study enrollment.
This trial requires 50 total participants across 1 different treatment group
This trial involves a single treatment. Consolidative Durvalumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"Around 80,000 people are diagnosed with NSCLC a year in the United States, making [lung cancer](https://www.withpower.com/clinical-trials/lung-cancer) the most common form of cancer in American women." - Anonymous Online Contributor
"Lung cancer is typically diagnosed at an advanced stage because of its typical nonspecific signs. Early detection has made it possible to cure a significant number of patients, who would otherwise have not received any potentially curative treatment. Most patients with stage I NSCLC can be cured. Most patients with stage II disease should be considered curable. Patients with stage III, localized disease, or high-grade histology have a low cure rate that is only marginally increased if the patient is treated with chemotherapy and/or radiation. Patients with metastatic disease have a survival considerably shorter than patients with localized disease. Only patients with a large tumor are curable in the vast majority of cases." - Anonymous Online Contributor
"Several treatments are used in the treatment of NSCLC and their use is based on many factors including the stage, metastatic disease, and comorbid diseases. The treatments used for NSCLC include surgery, chemotherapy-based regimes, radiation therapy, immunotherapy, targeted therapies and combinations." - Anonymous Online Contributor
"Symptoms vary from asymptomatic to acute and severe. The commonest symptoms were fever, malaise, weight loss and dyspnea. Symptoms were more frequently related to pleural or hilar involvement and were more common in stage III and IV disease. Symptoms were less common in stage IA. Symptoms were not specific for malignancy." - Anonymous Online Contributor
"Cancer of the lung is attributable to cigarette smoking, other risk factors including environmental tobacco smoke, and genetic susceptibility in some cases. The increased cancer risk with passive smoking has been documented in the UK and USA, and in studies in several other European countries. Cigarette smoking is the primary cause of lung cancer. Smoking must be avoided in order to reduce cancer risk." - Anonymous Online Contributor
"Carcinoma, non-small-cell lung is a clinical diagnosis and not a pathological diagnosis. Unlike in small-cell lung cancer, lymph node examination is generally not performed. We are currently considering the need to revisit the current guidelines for carcinoma, non-small-cell lung, as a more complete pathology report may help to identify tumors that are less likely to respond to treatment." - Anonymous Online Contributor
"Recent findings from multiple studies indicate that lung carcinoma spreads very quickly outside the bounds of the lung in the pleural space and in the pericardium or mediastinum. On the basis of this data, we advocate removal of the lung in all cases of carcinoma, regardless of any metastases already found." - Anonymous Online Contributor
"Most metastatic patients were treated with chemotherapy. The survival rate is comparable with other trials in stage IIIa-IIIb, including some of the most active chemotherapy regimens, which have been already tested in adjuvant settings. However, patients who are untreated have a better survival rate than patients who are treated and show a relevant improvement in survival, especially with chemotherapy plus thoracic radiotherapy. The improvement is not as large as obtained in some other trials, but should be discussed cautiously. The benefit of surgery of the lymph nodes has to be proven. Further randomized controlled trials, especially tailored and conducted with more advanced treatments in combination with the already known standard regimens should also be considered, especially when the survival rate drops significantly." - Anonymous Online Contributor
"Although durable response rates were not significantly improved, a trend towards better overall survival was noted. The benefit in OS was particularly obvious in patients under 75 years of age, but the effect was not statistically signifiant compared to other studies in patients of the same age group." - Anonymous Online Contributor
"The survival rate in this study was only 5.7% with a median survival of 7.5 months, lower than that reported in the literature. Survival rates are also lower at presentation and in the late stages of the disease. The survival rate for Stage III-IV is the lowest at 9.7% with a mean survival of 6.2 months." - Anonymous Online Contributor
"This phase 1 trial demonstrates durable results with durvalumab, especially in patients with HER2-positive/metschnikow tumor histology. Further studies are required to determine whether the combination of durvalumab and other drugs can prevent progression and prolong survival when used as a neoadjuvant." - Anonymous Online Contributor
"A significant fraction of NSCLC patients (≤ 30%) have a history of cancer within their families. These patients may benefit from genetic counselling and risk analysis during their pre-treatment evaluation. However, this information may not be useful for the selection of adjuvant treatment and decision to use neoadjuvant chemotherapy." - Anonymous Online Contributor